FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody or a functional fragment thereof, which are capable of binding with cMet. The invention also discloses a murine hybridoma capable of secreting the said antibody, a nucleic acid which expresses the said antibody and a kit for the prognosis of the effectiveness of treating an oncogenic disorder, which includes the said antibody. The invention discloses a method of detecting a cMet-expressing tumour, a method of diagnosing the cMet-expressing tumour, a method of determining the prognosis of the development of the cMet-expressing tumour and a method for the prognosis of the effectiveness of treating an oncogenic disorder using the disclosed anti-cMet antibody.
EFFECT: invention is capable of specifically binding with cMet, which provides the effective treatment of diseases associated with cMet polypeptide expression.
22 cl, 12 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| ANTI-CXCR4 ANTIBODIES FOR TREATMENT OF HIV INFECTION | 2010 |
|
RU2573902C2 |
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
